PH12013502401A1 - Novel compounds as diacylglycerol acyltransferase inhibitors - Google Patents
Novel compounds as diacylglycerol acyltransferase inhibitorsInfo
- Publication number
- PH12013502401A1 PH12013502401A1 PH1/2013/502401A PH12013502401A PH12013502401A1 PH 12013502401 A1 PH12013502401 A1 PH 12013502401A1 PH 12013502401 A PH12013502401 A PH 12013502401A PH 12013502401 A1 PH12013502401 A1 PH 12013502401A1
- Authority
- PH
- Philippines
- Prior art keywords
- dgat
- novel compounds
- diacylglycerol acyltransferase
- obesity
- acyltransferase inhibitors
- Prior art date
Links
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 title abstract 2
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002404 acyltransferase inhibitor Substances 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1452DE2011 | 2011-05-20 | ||
| US201161503728P | 2011-07-01 | 2011-07-01 | |
| PCT/US2012/038523 WO2012162129A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013502401A1 true PH12013502401A1 (en) | 2015-10-07 |
Family
ID=47217645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/502401A PH12013502401A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Country Status (34)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101919080B1 (ko) | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
| EP3492474B1 (en) | 2012-11-23 | 2021-08-11 | GlaxoSmithKline LLC | Intermediates used in the production of diacylglycerol acyltransferase inhibitors |
| WO2014081996A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| WO2015049668A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| WO2015049667A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| CN105732461A (zh) * | 2016-02-03 | 2016-07-06 | 常州工程职业技术学院 | 5-甲氧基-6-卤代吲哚的制备方法 |
| CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
| CN107619932B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| CN107619928B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| RU2706655C1 (ru) * | 2019-01-28 | 2019-11-19 | Акционерное общество "Гознак" (АО "Гознак") | Полимерсодержащее композиционное защищенное изделие |
| CN117603242B (zh) * | 2023-11-30 | 2026-08-11 | 沧州普瑞东方科技有限公司 | 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| KR101685718B1 (ko) * | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
| TW201038580A (en) * | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| JP2012520887A (ja) * | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| ES2513915T3 (es) | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| KR101919080B1 (ko) | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
-
2012
- 2012-05-18 KR KR1020137033509A patent/KR101919080B1/ko not_active Expired - Fee Related
- 2012-05-18 PT PT127899318T patent/PT2710013T/pt unknown
- 2012-05-18 DK DK12789931.8T patent/DK2710013T3/en active
- 2012-05-18 SG SG2013085501A patent/SG195044A1/en unknown
- 2012-05-18 LT LTEP12789931.8T patent/LT2710013T/lt unknown
- 2012-05-18 PL PL12789931T patent/PL2710013T3/pl unknown
- 2012-05-18 EA EA201391737A patent/EA023030B1/ru unknown
- 2012-05-18 SI SI201230689A patent/SI2710013T1/sl unknown
- 2012-05-18 CA CA2836669A patent/CA2836669C/en not_active Expired - Fee Related
- 2012-05-18 MY MYPI2013702195A patent/MY184553A/en unknown
- 2012-05-18 BR BR112013029935-5A patent/BR112013029935B1/pt not_active IP Right Cessation
- 2012-05-18 HU HUE12789931A patent/HUE028870T2/en unknown
- 2012-05-18 MX MX2013013566A patent/MX346494B/es active IP Right Grant
- 2012-05-18 CN CN201280035792.5A patent/CN103703009B/zh not_active Expired - Fee Related
- 2012-05-18 EP EP12789931.8A patent/EP2710013B1/en active Active
- 2012-05-18 WO PCT/US2012/038523 patent/WO2012162129A1/en not_active Ceased
- 2012-05-18 ES ES12789931.8T patent/ES2588748T3/es active Active
- 2012-05-18 AU AU2012259044A patent/AU2012259044B2/en not_active Ceased
- 2012-05-18 UA UAA201314878A patent/UA111360C2/uk unknown
- 2012-05-18 US US14/118,976 patent/US8859536B2/en not_active Expired - Fee Related
- 2012-05-18 RS RS20160648A patent/RS55006B1/sr unknown
- 2012-05-18 HR HRP20161089TT patent/HRP20161089T1/hr unknown
- 2012-05-18 PE PE2013002531A patent/PE20141204A1/es active IP Right Grant
- 2012-05-18 PH PH1/2013/502401A patent/PH12013502401A1/en unknown
- 2012-05-18 ME MEP-2016-159A patent/ME02479B/me unknown
- 2012-05-18 JP JP2014511575A patent/JP5844456B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-18 IL IL229488A patent/IL229488A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08664A patent/ZA201308664B/en unknown
- 2013-11-20 DO DO2013000272A patent/DOP2013000272A/es unknown
- 2013-11-20 CO CO13273126A patent/CO6811855A2/es active IP Right Grant
- 2013-11-20 CR CR20130602A patent/CR20130602A/es unknown
- 2013-12-13 MA MA36566A patent/MA35185B1/fr unknown
-
2014
- 2014-09-05 US US14/478,309 patent/US9040517B2/en not_active Expired - Fee Related
-
2015
- 2015-04-24 US US14/695,206 patent/US9273069B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 US US14/996,318 patent/US9540400B2/en not_active Expired - Fee Related
- 2016-09-19 CY CY20161100926T patent/CY1118188T1/el unknown
- 2016-09-20 SM SM201600328T patent/SMT201600328B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346494B (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa. | |
| MX2016010899A (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| PH12013502156A1 (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
| PH12013502262A1 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| MX347471B (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| MX2012007754A (es) | Derivados de pirazina y su uso en el tratamiento de transtornos neurologicos. | |
| MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
| PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| PH12013502403A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| PH12012502423B1 (en) | N-acyl amino acid derivatives for treating skin conditions such as cellulite | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
| WO2013181217A3 (en) | Novel compounds and compositions for treatment of breathing control disorders or diseases | |
| WO2014074761A3 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| PH12015501109A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| MX2015001677A (es) | Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion. | |
| MX364643B (es) | USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. | |
| WO2013068993A3 (en) | Tyrosine isomers as therapeutic agents |